I see a lot of misinformation on this board. If you want to invest in a stock then you have to do a lot of reading and listening and put the pieces together. They could have been a bit clearer at the conference last week but if you go to the Nov 14 update. http://finance.yahoo.com/news/ampio-provides-progress-report-clinical-090000253.html under the last bullet point for Zertane.
'Ampio has contracted Pharmerit, Inc. (Cambridge, MA) to complete the development of the Patient Outcome for Premature #$%$ (POPE) patient reported outcome (PRO) tool for the evaluation of premature #$%$ therapy. When completed in the next few weeks this will be the only validated PRO tool for PE in the FDA environment. The completion of the POPE trial will allow Ampio to file the IND in the USA and conclude its negotiations with pharmaceutical partners.'
So the trial or study referred to is the POPE study. This trial is complete. This is a way to basically validate a premature ej. drug. Imagine if you will, collecting data for such a study…does the guy sit there with a stopwatch? How is satisfaction measured? So much thought has to be put into the design and validation parameters of such a study. This is the objective of POPE. This study is now complete and filed as part of IND. INDs take 30 business days for FDA response. If the FDA accepts then Ampio can conclude negotiations and offload Zertane to partner(s). I took this as extremely + news. This announcement could happen any day.
Other positive news coming:
• IND acceptance and start of Ampio trial.
• Announcement of ORP spinoff.
• Possible additional coverage by '2 firms' mentioned in Noble conference.
• Filing for approval of Zertane™, based on the European trials results, in Australia (TGA). - I don’t think this was filed as of yet. Might be holding off and letting the ‘partner’ handle this.
Also, if you ever have any questions just call Ampio and ask to speak to investor relations. They have always been good about answering my questions. Rick Giles (720) 437-6530.
No I don’t work for Ampio but am a very large investor that believes in the company.